third parties make in the United States which could replace the subject articles if they were to be excluded;

(iv) indicate whether complainant, complainant's licensees, and/or third-party suppliers have the capacity to replace the volume of articles potentially subject to the recommended general exclusion order within a commercially reasonable time; and

(v) explain how the recommended general exclusion order would impact consumers in the United States.

Written submissions must be filed no later than by close of business on May 8, 2020.

Persons filing written submissions must file the original document electronically on or before the deadlines stated above. The Commission's paper filing requirements in 19 CFR 210.4(f) are currently waived. 85 FR 15798 (March 19, 2020).

Any person desiring to submit a document to the Commission in confidence must request confidential treatment. All such requests should be directed to the Secretary to the Commission and must include a full statement of the reasons why the Commission should grant such treatment. *See* 19 CFR 201.6. Documents for which confidential treatment by the Commission is properly sought will be treated accordingly. All information, including confidential business information and documents for which confidential treatment is properly sought, submitted to the Commission for purposes of this Investigation may be disclosed to and used: (i) By the Commission, its employees and Offices, and contract personnel (a) for developing or maintaining the records of this or a related proceeding, or (b) in internal investigations, audits, reviews, and evaluations relating to the programs, personnel, and operations of the Commission including under 5 U.S.C. Appendix 3; or (ii) by U.S. government employees and contract personnel,[1] solely for cybersecurity purposes. All nonconfidential written submissions will be available for public inspection at the Office of the Secretary and on EDIS.

This action is taken under the authority of section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and in part 210 of the Commission's Rules of Practice and Procedure (19 CFR part 210).

By order of the Commission.

[1] All contract personnel will sign appropriate nondisclosure agreements.

Issued: April 16, 2020.

Lisa Barton,

Secretary to the Commission.

[FR Doc. 2020–08479 Filed 4–21–20; 8:45 am]

BILLING CODE 7020–02–P

INTERNATIONAL TRADE COMMISSION

[Investigation No. 337–TA–1116]

Certain Blood Cholesterol Testing Strips and Associated Systems Containing the Same; Commission's Final Determination Finding a Violation of Section 337; Issuance of a Limited Exclusion Order; Termination of Investigation

AGENCY: U.S. International Trade Commission.

ACTION: Notice.

SUMMARY: Notice is hereby given that the U.S. International Trade Commission has found a violation of section 337 of the Tariff Act of 1930, as amended, by ACON Biotech (Hangzhou) Co., Ltd. of Hangzhou, China, and ACON Laboratories, Inc., of San Diego, California, and has determined to issue a limited exclusion order. The investigation is terminated.

FOR FURTHER INFORMATION CONTACT: Robert Needham, Office of the General Counsel, U.S. International Trade Commission, 500 E Street SW, Washington, DC 20436, telephone (202) 708–5468. Copies of non-confidential documents filed in connection with this investigation may be viewed on the Commission's electronic docket (EDIS) at *https://edis.usitc.gov.* For help accessing EDIS, please email *EDIS3Help@usitc.gov.* General information concerning the Commission may also be obtained by accessing its internet server (*https://www.usitc.gov*). Hearing-impaired persons are advised that information on this matter can be obtained by contacting the Commission's TDD terminal, telephone (202) 205–1810.

SUPPLEMENTARY INFORMATION: The Commission instituted this investigation on June 5, 2018, based on a complaint filed by Polymer Technology Systems, Inc. of Indianapolis, Indiana (''PTS''). 83 FR 26087–88. The complaint alleges violations of section 337 in the importation into the United States, the sale for importation, and the sale after importation within the United States after importation of certain blood cholesterol testing strips and associated systems containing the same by reason of infringement of one or more claims of U.S. Patent Nos. 7,087,397 (''the '397 patent''); 7,625,721 (''the '721 patent''); and 7,494,818 (''the '818 patent''). *Id.* at 26087. The notice of investigation named as respondents ACON Laboratories, Inc. of San Diego, California (''ACON Labs''), and ACON Biotech (Hangzhou) Co., Ltd. of Hangzhou, China (''ACON Bio'') (collectively, ''ACON''). The Office of Unfair Import Investigations is not a party to the investigation. *Id.* at 26088.

The Commission subsequently terminated the investigation with respect to claims 10, 13, 14, and 20 of the '397 patent based on PTS's withdrawal of those allegations. *See* Order. No. 7 (Sept. 10, 2018), *not reviewed,* Notice (Sept. 25, 2018); Order No. 10 (Jan. 31, 2019), *not reviewed,* Notice (Feb. 21, 2019). The Commission also terminated the investigation for infringement purposes with respect to claim 17 of the '397 patent; claims 2, 3, 13, and 14 of the '721 patent; and claim 10 of the '818 patent based on PTS's withdrawal of allegations. Order No. 14 (Feb. 14, 2019), *not reviewed,* Notice (Mar. 5, 2019). Finally, the Commission terminated the investigation with respect to claims 1–3, 5, and 18 of the '397 patent and claims 5, 7, and 9 of the '721 patent based on PTS's withdrawal of allegations. Order No. 15 (Mar. 12, 2019), *not reviewed,* Notice (April 9, 2019). Accordingly, at the time of the Final ID, PTS asserted for infringement claim 19 of the '397 patent; claims 1, 4, 6, 8, and 15 of the '721 patent; and claims 8, 9, and 11 of the '818 patent. Final ID at 43.

On February 13, 2019, the presiding administrative law judge (''ALJ'') issued an initial determination (''ID'') granting a summary determination that PTS satisfied the economic prong of the domestic industry requirement for each of three asserted patents under section 337(a)(3)(A), (B), and (C). Order No. 13 (Feb. 13, 2019). No party petitioned for review of the ID, and the Commission declined to review the ID. Notice (Mar. 12, 2019).

On June 4, 2019, the ALJ issued a final ID finding a violation of section 337 with respect to the '397 and '721 patents, and no violation with respect to the '818 patent. The ALJ found that ACON infringed claim 19 of the '397 patent and claims 1, 4, 6, 7, and 15 of the '721 patent, but did not infringe claims 8, 9, and 11 of the '818 patent. The ALJ also found that PTS satisfies the domestic industry requirement with respect to all three asserted patents, and that no asserted claims were shown to be invalid by clear and convincing evidence.

On June 17, 2019, ACON petitioned for review of the final ID with respect

to the '397 and '721 patents, and contingently petitioned for review of the final ID with respect to the '818 patent. PTS did not file a petition for review, and, on June 25, 2019, PTS filed a response to ACON's petition.

On August 13, 2019, the Commission determined to review the Final ID in part. Specifically, the Commission determined to review the following issues: (1) Whether ACON Labs' use of the accused products in the United States constitutes a violation of 19 U.S.C. 1337(a)(1)(B)(i); (2) the final ID's construction of ''reacting HDL . . . without precipitating said one or more non-selected analytes'' in the '721 patent, as well as related findings on infringement, the domestic industry, and invalidity; and (3) the final ID's finding that all of the asserted claims of the '721 patent are not shown to be invalid for a lack of enablement. The Commission did not review any other findings presented in the final ID.

The Commission also sought briefing from the parties on four issues and on remedy, bonding, and public interest. On August 27, 2019, PTS and ACON filed their initial submissions in response to the Commission's request for briefing. On September 3, 2019, PTS and ACON filed their reply submissions in response to the Commission's request for briefing. No third-party submissions on remedy, bonding, or the public interest were received.

Having examined the record of this investigation, including the Final ID, the petition, response, and other submissions from the parties, the Commission has determined that PTS has shown a violation of section 337 by ACON Bio and ACON Labs with respect to the '397 and '721 patents. The Commission has also determined to construe the term ''precipitating'' to mean ''separating a solid substance or material from a solution by a chemical reaction,'' and finds that, under this construction, PTS established infringement and the domestic industry requirement with respect to claims 1, 4, 6, 8, and 15 of the '721 patent, and that ACON failed to show that any claim is invalid by clear and convincing evidence. The Commission's determinations are explained more fully in the accompanying Opinion. All other findings in the ID under review that are consistent with the Commission's determinations are affirmed.

The Commission has determined that the appropriate form of relief in this investigation is a limited exclusion order with respect to ACON Bio and ACON Labs prohibiting the importation of imported blood cholesterol testing strips and associated systems containing the same that are covered by one or more of claim 19 of the '397 patent and claims 1, 4, 6, 8, and 15 of the '721 patent. The Commission has further determined that the public interest factors enumerated in subsection 337(d)(1) (19 U.S.C. 1337(d)(1)) do not preclude the issuance of the limited exclusion order. Finally, the Commission has determined that the bond for importation during the period of Presidential review shall be in the amount of zero percent of the entered value of such articles.

The Commission's notice, order, and opinion were delivered to the President and to the United States Trade Representative on the day of their issuance. The Commission has also notified the Secretary of the Treasury and Customs and Border Protection of the order. The investigation is hereby terminated.

The authority for the Commission's determination is contained in section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and in part 210 of the Commission's Rules of Practice and Procedure (19 CFR part 210).

By order of the Commission.

Issued: April 16, 2020.

Lisa Barton,

Secretary to the Commission.

[FR Doc. 2020–08480 Filed 4–21–20; 8:45 am]

BILLING CODE 7020–02–P

DEPARTMENT OF JUSTICE

Bureau of Alcohol, Tobacco, Firearms and Explosives

[OMB Number 1140–0056]

Agency Information Collection Activities; Proposed eCollection eComments Requested; Special Agent Medical Preplacement—ATF Form 2300.10

AGENCY: Bureau of Alcohol, Tobacco, Firearms and Explosives, Department of Justice.

ACTION: 30-Day notice.

SUMMARY: The Department of Justice (DOJ), Bureau of Alcohol, Tobacco, Firearms and Explosives (ATF), will submit the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995.

DATES: Comments are encouraged and will be accepted for an additional 30 days until May 22, 2020.

FOR FURTHER INFORMATION CONTACT: Written comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to *www.reginfo.gov/public/do/PRAMain.* Find this particular information collection by selecting ''Currently under 30-day Review—Open for Public Comments'' or by using the search function.

SUPPLEMENTARY INFORMATION: Written comments and suggestions from the public and affected agencies concerning the proposed collection of information are encouraged. Your comments should address one or more of the following four points:

—Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;

—Evaluate the accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;

—Evaluate whether and if so how the quality, utility, and clarity of the information to be collected can be enhanced; and

—Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, *e.g.,* permitting electronic submission of responses.

Overview of This Information Collection

(1) *Type of Information Collection:* Revision of a currently approved collection.

(2) *The Title of the Form/Collection:* Special Agent Medical Preplacement.

(3) *The agency form number, if any, and the applicable component of the Department sponsoring the collection:*

Form number: ATF Form 2300.10.

Component: Bureau of Alcohol, Tobacco, Firearms and Explosives, U.S. Department of Justice.

(4) *Affected public who will be asked or required to respond, as well as a brief abstract:*

Primary: Individuals or households.

Other: Federal Government.

Abstract: The Special Agent Medical Preplacement Form—ATF Form 2300.10 is used to collect specific personally identifiable information (PII), including the name, address, telephone, social security number and certain medical data. The collected medical data is used to determine if a candidate is medically